The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an expanded indication for Pepaxti for patients receiving third-line treatment for multiple myeloma. The opinion may mean that more patients gain access to the treatment earlier in the course of the disease. In an interview with BioStock, CEO Sofia Heigis comments on the significance for patients, markets and Oncopeptides’ continued growth.
The interview is in Swedish.